Literature DB >> 16033750

The Prevalence of Demodex folliculorum in blepharitis patients and the normal population.

Mustafa Kemal1, Zeynep Sümer, Mustafa Ilker Toker, Haydar Erdoğan, Aysen Topalkara, Makbule Akbulut.   

Abstract

PURPOSE: Demodex folliculorum (DF), which is frequently found in patients with chronic blepharitis, is a well-known common inhabitant of eyelash follicles. In the present study, the prevalence of DF in seborrheic blepharitis patients and controls was investigated. In addition, the associations between the presence of DF and host factors (age, sex) were analyzed.
METHODS: A prospective, cross-sectional study was done involving 500 cases. In all, 6000 cilia from 170 patients with seborrheic blepharitis and 330 patients with normal eyes were examined for DF. Twelve eyelash samples were epilated from each patient and examined under the light microscope.
RESULTS: DF was found in 28.8% (49/170) of patients with blepharitis and in 26.7% (88/330) of controls. The difference between the two groups was not statistically significant. The overall prevalence was 27.4% (137/500) in all patients. Although the prevalence of DF increased with increasing age, no significant difference was found between the age groups. There was also no statistically significant difference for DF prevalence between males (28.9%; 71/246) and females (24.1%; 61/254).
CONCLUSION: Our findings show a high DF prevalence in both blepharitis and control patients and no relationship was found between the presence of DF and host factors (age, sex).

Entities:  

Mesh:

Year:  2005        PMID: 16033750     DOI: 10.1080/092865805910057

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  25 in total

Review 1.  [Blepharitis component of dry eye syndrome].

Authors:  C Auw-Hädrich; T Reinhard
Journal:  Ophthalmologe       Date:  2018-02       Impact factor: 1.059

2.  Sociodemographic characteristics and risk factor analysis of Demodex infestation (Acari: Demodicidae).

Authors:  Ya-e Zhao; Na Guo; Meng Xun; Ji-ru Xu; Mei Wang; Duo-lao Wang
Journal:  J Zhejiang Univ Sci B       Date:  2011-12       Impact factor: 3.066

Review 3.  [Treatment options for chronic blepharitis considering current evidence].

Authors:  C Auw-Hädrich; T Reinhard
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

Review 4.  Ocular Demodicosis as a Potential Cause of Ocular Surface Inflammation.

Authors:  Xiaohui Luo; Jing Li; Chuan Chen; Scheffer Tseng; Lingyi Liang
Journal:  Cornea       Date:  2017-11       Impact factor: 2.651

5.  Ocular Demodex folliculorum: prevalence and associated symptoms in an Irish population.

Authors:  Orla Murphy; Veronica O'Dwyer; Aoife Lloyd-McKernan
Journal:  Int Ophthalmol       Date:  2018-01-29       Impact factor: 2.031

6.  Occurrence of Demodex species in patients with blepharitis and in healthy individuals: a 10-year observational study.

Authors:  Monika Maria Biernat; Jolanta Rusiecka-Ziółkowska; Elżbieta Piątkowska; Iwona Helemejko; Paweł Biernat; Grażyna Gościniak
Journal:  Jpn J Ophthalmol       Date:  2018-09-25       Impact factor: 2.447

7.  Demodex treatment in external ocular disease: the outcomes of a Tasmanian case series.

Authors:  Stephen G Nicholls; Carmen L Oakley; Andrea Tan; Brendan J Vote
Journal:  Int Ophthalmol       Date:  2016-02-02       Impact factor: 2.031

8.  Tea tree oil for Demodex blepharitis.

Authors:  Keyur Savla; Jimmy T Le; Andrew D Pucker
Journal:  Cochrane Database Syst Rev       Date:  2020-06-20

9.  Terpinen-4-ol is the Most Active Ingredient of Tea Tree Oil to Kill Demodex Mites.

Authors:  Sean Tighe; Ying-Ying Gao; Scheffer C G Tseng
Journal:  Transl Vis Sci Technol       Date:  2013-11-13       Impact factor: 3.283

10.  Randomized double-blind trial of wipes containing terpinen-4-ol and hyaluronate versus baby shampoo in seborrheic blepharitis patients.

Authors:  Ceyhun Arici; Burak Mergen; Ayse Yildiz-Tas; Hrisi Bahar-Tokman; Edip Tokuc; Yesim Ozturk-Bakar; Zekayi Kutlubay; Afsun Sahin
Journal:  Eye (Lond)       Date:  2021-06-28       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.